TGTX

+ Watchlist + Portfolio

TG Therapeutics, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $53.62
52-Week Range: $26.76 – $59.30
Market Cap: $8.31B
P/E (TTM): 19.74
EPS (TTM): 2.75
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 13.20
PEG Ratio: 1.61
Return on Equity: 100.28%
Return on Assets: 7.28%
Gross Margin: 82.37%
Operating Margin: 9.02%
Profit Margin: 55.22%
Current Ratio: 4.27
Debt/Equity: 1.25
Total Debt: $754.44M
Free Cash Flow: $59.13M
Revenue Growth: 70.30%
Earnings Growth: -70.60%
Enterprise Value: $7.90B

TGTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.79M	$233.66M	$329.00M	$616.29M
Cost of Revenue	$265.00K	$14.13M	$38.49M	$100.71M
Gross Profit	$2.52M	$219.53M	$290.52M	$515.57M
Research & Development	$125.35M	$76.19M	$94.29M	$160.22M
Selling, General & Admin	$95.48M	$122.71M	$154.30M	$232.03M
Operating Expenses	$220.84M	$198.90M	$248.59M	$392.25M
Operating Income	-$218.32M	$20.63M	$41.93M	$123.32M
EBITDA	-$213.11M	$26.10M	$49.90M	$134.36M
Pretax Income	-$223.81M	$13.06M	$25.59M	$107.39M
Income Tax	$0.00	$390.00K	$2.21M	-$339.79M
Net Income	-$223.81M	$12.67M	$23.38M	$447.18M
Diluted EPS	-1.46	0.09	0.15	2.77
Diluted Shares	135.41M	148.51M	160.34M	161.41M

TGTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$102.30M	$92.93M	$179.89M	$79.15M
Receivables	$0.00	$51.09M	$129.19M	$305.63M
Inventory	$0.00	$39.82M	$110.46M	$125.59M
Current Assets	$168.27M	$317.94M	$566.36M	$630.76M
Total Assets	$193.57M	$329.59M	$577.69M	$1.06B
Current Liabilities	$53.20M	$53.72M	$90.68M	$153.76M
Long-Term Debt	$71.14M	$100.12M	$244.43M	$245.65M
Total Debt	$83.06M	$110.80M	$253.72M	$253.71M
Total Liabilities	$134.99M	$169.09M	$355.33M	$415.23M
Retained Earnings	-$1.53B	-$1.55B	-$1.53B	-$1.08B
Shareholders' Equity	$58.59M	$160.50M	$222.36M	$648.02M
Working Capital	$115.07M	$264.22M	$475.68M	$477.00M
Net Debt	—	$7.18M	$64.53M	$166.50M

TGTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$176.17M	-$31.41M	-$40.52M	-$24.77M
Capital Expenditure	-$14.00K	—	-$45.00K	-$214.00K
Free Cash Flow	-$176.18M	-$31.41M	-$40.56M	-$24.99M
Depreciation & Amortisation	$515.00K	$423.00K	$280.00K	$244.00K
Stock-Based Compensation	$44.66M	$37.93M	$42.54M	$64.67M
Investing Cash Flow	-$20.01M	-$50.65M	-$1.04M	$13.80M
Financing Cash Flow	-$391.00K	$72.70M	$128.53M	-$89.73M
Share Repurchases	$0.00	$0.00	-$8.76M	-$91.24M
Net Change in Cash	-$196.57M	-$9.36M	$86.97M	-$100.70M

TGTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$120.86M	$141.15M	$161.71M	$192.57M	$204.92M	$240.34M
Cost of Revenue	$15.54M	$18.94M	$28.09M	$38.14M	$33.51M	$41.19M
Gross Profit	$105.31M	$122.21M	$133.62M	$154.43M	$171.41M	$199.14M
Research & Development	$46.36M	$31.78M	$40.88M	$41.19M	$48.40M	$95.34M
Selling, General & Admin	$50.33M	$55.59M	$63.37M	$62.74M	$88.22M	$82.13M
Operating Expenses	$96.69M	$87.37M	$104.25M	$103.94M	$136.61M	$177.47M
Operating Income	$8.62M	$34.84M	$29.36M	$50.49M	$34.80M	$21.67M
EBITDA	$12.28M	$37.70M	$32.69M	$51.69M	$28.11M	$26.90M
Pretax Income	$5.47M	$30.92M	$25.91M	$45.09M	$20.36M	$10.23M
Income Tax	$408.00K	$2.73M	-$364.99M	$22.06M	$586.00K	$2.45M
Net Income	$5.06M	$28.19M	$390.89M	$23.04M	$19.78M	$7.78M
Diluted EPS	0.03	0.17	2.43	0.14	0.12	0.05
Diluted Shares	162.77M	162.56M	161.00M	159.37M	160.06M	157.28M

TGTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$132.14M	$129.13M	$74.08M	$79.15M	$442.21M	$482.57M
Receivables	$190.12M	$231.52M	$265.38M	$305.63M	$392.05M	$401.56M
Inventory	$157.76M	$155.20M	$146.95M	$125.59M	$129.03M	$147.97M
Current Assets	$644.51M	$663.96M	$599.76M	$630.76M	$1.09B	$1.15B
Total Assets	$656.69M	$702.61M	$1.03B	$1.06B	$1.53B	$1.64B
Current Liabilities	$160.21M	$171.89M	$156.81M	$153.76M	$187.11M	$268.49M
Long-Term Debt	$244.73M	$245.04M	$245.34M	$245.65M	$745.14M	$745.39M
Total Debt	$253.71M	$253.72M	$253.72M	$253.71M	$753.56M	$754.44M
Total Liabilities	$419.40M	$426.18M	$417.81M	$415.23M	$945.71M	$1.04B
Retained Earnings	-$1.52B	-$1.50B	-$1.11B	-$1.08B	-$1.06B	-$1.05B
Shareholders' Equity	$237.29M	$276.43M	$607.22M	$648.02M	$583.13M	$604.08M
Working Capital	$484.30M	$492.07M	$442.95M	$477.00M	$899.86M	$877.19M
Net Debt	$112.59M	$115.91M	$171.26M	$166.50M	$302.93M	$262.81M

TGTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$28.71M	$7.44M	-$23.15M	$19.66M	-$17.89M	$39.26M
Capital Expenditure	-$25.00K	-$42.00K	-$80.00K	-$67.00K	-$51.00K	-$293.00K
Free Cash Flow	-$28.74M	$7.39M	-$23.23M	$19.59M	-$17.95M	$38.97M
Depreciation & Amortisation	$56.00K	$59.00K	$62.00K	$67.00K	$80.00K	$96.00K
Stock-Based Compensation	$14.97M	$16.36M	$17.69M	$15.65M	$19.95M	$27.88M
Investing Cash Flow	-$12.93M	-$3.99M	$46.36M	-$15.64M	-$9.86M	$1.03M
Financing Cash Flow	-$6.10M	-$6.44M	-$78.24M	$1.06M	$390.83M	$85.00K
Dividends Paid	$0.00	$0.00	—	—	$0.00	$0.00
Share Repurchases	-$6.12M	-$6.88M	-$78.24M	$0.00	-$99.99M	$0.00
Net Change in Cash	-$47.75M	-$3.00M	-$55.03M	$5.08M	$363.07M	$40.38M

Market Snapshot

About

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, including chronic lymphocytic leukemia (CLL) and multiple sclerosis. The company markets BRIUMVI for relapsing forms of multiple sclerosis and continues advancing its pipeline of targeted immunotherapies.